Inhibikase Therapeutics (IKT) Assets Average (2021 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Assets Average for 5 consecutive years, with $84.2 million as the latest value for Q3 2025.
- Quarterly Assets Average rose 1175.76% to $84.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $84.2 million through Sep 2025, up 1175.76% year-over-year, with the annual reading at $56.6 million for FY2024, 186.76% up from the prior year.
- Assets Average for Q3 2025 was $84.2 million at Inhibikase Therapeutics, down from $91.6 million in the prior quarter.
- The five-year high for Assets Average was $96.4 million in Q1 2025, with the low at $6.6 million in Q3 2024.
- Average Assets Average over 5 years is $37.4 million, with a median of $30.5 million recorded in 2021.
- The sharpest move saw Assets Average tumbled 67.18% in 2024, then surged 1175.76% in 2025.
- Over 5 years, Assets Average stood at $44.2 million in 2021, then tumbled by 39.42% to $26.8 million in 2022, then tumbled by 39.48% to $16.2 million in 2023, then skyrocketed by 217.95% to $51.5 million in 2024, then surged by 63.58% to $84.2 million in 2025.
- According to Business Quant data, Assets Average over the past three periods came in at $84.2 million, $91.6 million, and $96.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.